TB-500 is a short synthetic peptide, just seven amino acids: Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln (written LKKTETQ, with an acetyl cap). That sequence is not random. It copies residues 17 to 23 of thymosin beta-4 (Tβ4), a 43-amino-acid protein that your cells make naturally and that shows up in wound fluid. So TB-500 is best understood as a fragment of a real human protein rather than a designed drug.
A distinction matters here, because product pages routinely blur it. TB-500 and thymosin beta-4 are not the same molecule. Tβ4 is the full protein. TB-500 is a small slice of it that happens to contain the part responsible for binding actin. The two get marketed interchangeably, but almost all of the better human clinical data is on full-length Tβ4, not on the LKKTETQ heptapeptide that gets sold as "TB-500."
What it does at the molecular level
Thymosin beta-4's main job is to bind and sequester G-actin, the monomer form of actin. By holding a reservoir of actin monomers, it helps regulate how much actin is free to polymerize into the filaments that let cells change shape and crawl. That actin-handling is what underlies its links to cell migration, new blood-vessel formation, and tissue repair.
The interesting finding for TB-500 specifically: the small actin-binding motif carries a lot of that activity on its own. In work by Sosne and colleagues in The FASEB Journal (2010), short peptides built around the LKKTETQ sequence reproduced much of the full protein's effect on angiogenesis, cell migration, and dermal wound healing. An earlier FASEB Journal study had already pinned the actin-binding site as the part driving angiogenesis. The LKKTETQ peptide also turns up naturally in wound fluid as a breakdown product of Tβ4, so it isn't purely a lab artifact.
The state of the evidence
Most of the peer-reviewed and clinical work is on Tβ4, the whole protein. RegeneRx Biopharmaceuticals licensed Tβ4 from the NIH and ran placebo-controlled trials of a topical Tβ4 gel in chronic wounds, including pressure ulcers and venous stasis ulcers. Those studies looked at safety and healing rates. That is a real clinical record, but it is the full protein and a topical formulation, not the injectable heptapeptide.
For the TB-500 fragment itself, controlled human data has been thin. That is starting to change: a Phase 1/2, randomized, double-blind, placebo-controlled dose-escalation study of TB-500 (the thymosin beta 4 17-23 fragment) is recruiting adults with stable atherosclerotic cardiovascular disease, sponsored by Hudson Biotech, primarily to test safety and tolerability. It's early-stage and its primary endpoints are adverse-event counts, not efficacy claims. The muscle, tendon, and joint-repair uses TB-500 is best known for in the gym world rest mostly on animal studies and lab models, not finished human trials.
Sport, racing, and regulatory status
TB-500 has a notable history in horse racing. It was circulated in veterinary contexts for soft-tissue and joint repair, and by the early 2010s there were concerns about its use in racehorses, which pushed labs to develop detection tests. Thymosin beta-4 and its fragments are now banned in racing and in human sport.
For athletes, TB-500 is prohibited at all times by the World Anti-Doping Agency; Tβ4 and its derivatives fall under WADA's growth-factor provisions. It is not an approved drug. In the U.S. the FDA has placed it in a category of bulk substances flagged with safety concerns and not permitted for pharmacy compounding, and it is not a lawful dietary-supplement ingredient.
The buyer-quality angle
Because nothing sold as "TB-500" is an approved product, what's in the vial varies. Independent analyses of research-grade peptides have flagged problems like truncated or incomplete sequences, degradation from poor storage, endotoxin and microbial contamination, and plain mislabeling, with wide swings in purity and potency between suppliers. The short version: identity and purity are not guaranteed by the label. Anyone evaluating a vendor should look for a recent third-party certificate of analysis (mass-spec identity plus an HPLC purity figure) tied to the specific lot, and treat "research use only" as exactly that.
None of this is medical or dosing advice. TB-500 is sold for laboratory research only and is not approved for human use.